Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

ClinicalTrials.gov ID: NCT02441283

Public ClinicalTrials.gov record NCT02441283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.

Study identification

NCT ID
NCT02441283
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
384 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 21, 2015
Primary completion
Oct 14, 2019
Completion
Oct 14, 2019
Last update posted
Sep 20, 2020

2015 – 2019

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Digestive Health Specialists of the Southeast /ID# 136725 Dothan Alabama 36305
Felizarta /ID# 141033 Bakersfield California 93301
Southern California Res. Ctr. /ID# 141799 Coronado California 92118-1408
Research & Education, Inc. /ID# 169591 San Diego California 92105
eStudySite San Diego /ID# 141040 San Diego California 92120
eStudySite San Diego /ID# 141047 San Diego California 92120
eStudySite San Diego /ID# 141048 San Diego California 92120
Midway Immunology and Research /ID# 169477 Ft. Pierce Florida 34982
Delta Research Partners /ID# 141028 Bastrop Louisiana 71220
Louisiana Research Ctr. LLC /ID# 141024 Shreveport Louisiana 71105-6800
Henry Ford Health System /ID# 141039 Detroit Michigan 48202
Binghamton Gastroenterology /ID# 141026 Binghamton New York 13903
Carolinas Center for Liver Dis /ID# 155390 Statesville North Carolina 28677-3471
Northwest Gastroenterology Cli /ID# 141036 Portland Oregon 97210
Gastro One /ID# 169478 Germantown Tennessee 38138
Quality Medical Research, PLLC /ID# 141042 Nashville Tennessee 37211
TX Clinical Research Institute /ID# 141037 Arlington Texas 76012
Inquest Clinical Research /ID# 141045 Baytown Texas 77521-2415
TX Liver Inst, Americ Res Corp /ID# 136727 San Antonio Texas 78215
Bon Secours St. Mary's Hospita /ID# 165106 Richmond Virginia 23226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02441283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02441283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →